The 282 references in paper Article Editorial , Статья Редакционная (2017) “Легочная гипертензия. Диагностика и лечение. Европейские клинические рекомендации (2015) (часть 2-я) // Pulmonary hypertension. Diagnosis and therapy. European guidelines, 2015 (Part 2)” / spz:neicon:pulmonology:y:2017:i:4:p:447-471

1
Hoeper M.M., Bogaard H.J., Condliffe R. et al. Definitions and diagnosis of pulmonary hypertension. J. Am. Coll. Cardiol.2013; 62 (Suppl.): D42–D50. DOI: 10.1016/j. jacc.2013.10.032.
(check this in PDF content)
2
Kovacs G., Berghold A., Scheidl S. et al. Pulmonary arterial pressure during rest and exercise in healthy subjects: A systematic review.Eur. Respir. J. 2009; 34 (4): 888–894. DOI: 10.1183/09031936.00145608.
(check this in PDF content)
3
Herve P., Lau E., Sitbon O. et al. Criteria for diagnosis of exercise pulmonary hypertension. Eur. Respir. J.2015;
(check this in PDF content)
4
3): 728–737. DOI: 10.1183/09031936.00021915. 4. Vachiery J.L., Adir Y., Barbera J.A. et al. Pulmonary hypertension due to left heart disease. J. Am. Coll. Cardiol. 2013; 62 (25, Suppl.): D100–D108. DOI: 10.1016/j.jacc. 2013.10.033.
(check this in PDF content)
5
Simonneau G., GalièN., Rubin L.J. et al. Clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 2004; 43 (Suppl. 1): S5–S12.
(check this in PDF content)
6
Simonneau G., Gatzoulis M.A., Adatia I. et al. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 2013; 62 (25, Suppl.): D34–D41. DOI: 10. 1016/j.jacc.2013.10.029.
(check this in PDF content)
7
Dhillon R. The management of neonatal pulmonary hypertension.Arch. Dis. Child Fetal. Neonatal. Ed.2012; 97 (3): F223–F228. DOI: 10.1136/adc.2009.180091.
(check this in PDF content)
8
Porta N.F., Steinhorn R.H. Pulmonary vasodilator therapy in the NICU: inhaled nitric oxide, sildenafil, and other pulmonary vasodilating agents.Clin. Perinatol.2012; 39 (1): 149–164. DOI: 10.1016/j.clp.2011.12.006.
(check this in PDF content)
9
Ivy D.D., Abman S.H., Barst R.J. et al. Pediatric pulmonary hypertension. J. Am. Coll. Cardiol. 2013; 62 (25, Suppl.): D117–D126. DOI: 10.1016/j.jacc.2013.10.028.
(check this in PDF content)
10
Humbert M., Sitbon O., Chaouat A. et al. Pulmonary arterial hypertension in France: results from a national registry.Am. J. Respir. Crit. Care Med. 2006; 173 (9): 1023–1030. DOI: 10.1164/rccm.200510-1668OC.
(check this in PDF content)
11
Peacock A.J., Murphy N.F., McMurray J.J.V. et al. An epidemiological study of pulmonary arterial hypertension. Eur. Respir. J. 2007; 30 (1): 104–109. DOI: 10.1183/0903 1936.00092306.
(check this in PDF content)
12
McGoon M.D., Benza R.L., Escribano-Subias P. et al. Pulmonary arterial hypertension: epidemiology and registries.J. Am. Coll. Cardiol.2013; 62 (25, Suppl.): D51–D59.
(check this in PDF content)
13
Simonneau G., Robbins I., Beghetti M., et al. Updated clinical classification of pulmonary hypertension.J. Am. Coll. Cardiol.2009; 54 (Suppl.): S43–S54.
(check this in PDF content)
14
Montani D., Bergot E., Günther S. et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012; 125 (17): 2128–2137. DOI: 10.1161/ CIRCULATIONAHA.111.079921.
(check this in PDF content)
15
Savale L., Chaumais M.C., Cottin V. et al. Pulmonary hypertension associated with benfluorex exposure. Eur. Respir. J.2012; 40 (5): 1164–1172. DOI: 10.1183/0903 1936.00188611.
(check this in PDF content)
16
Savale L., Sattler C., Gunther S. et al. Pulmonary arterial hypertension in patients treated with interferon. Eur. Respir. J.2014; 44 (6): 1627–1634. DOI: 10.1183/0903 1936.00057914.
(check this in PDF content)
17
Badesch B.D., Champion H.C., Gomez-Sanchez M.A. et al. Diagnosis and assessment of pulmonary arterial hypertension.J. Am. Coll. Cardiol.2009; 54 (Suppl.): S55–S56.
(check this in PDF content)
18
Oudiz R.J. Pulmonary hypertension associated with leftsided heart disease.Clin. Chest Med.2007; 28 (1): 233– 241. DOI: 10.1016/j.ccm.2006.12.001.
(check this in PDF content)
19
Vahanian A., Alfieri O., Andreotti F. et al. Guidelines on the management of valvular heart disease (version 2012). Eur. Heart J. 2012; 33 (19): 2451–2496. DOI: 10.1093/ eurheartj/ehs109.
(check this in PDF content)
20
Seeger W., Adir Y., BarberàJ.A. et al. Pulmonary hypertension in chronic lung diseases. J. Am. Coll. Cardiol. 2013; 62 (25, Suppl.): D109–D116.
(check this in PDF content)
21
Hurdman J., Condliffe R., Elliot C.A. et al. Pulmonary hypertension in COPD: results from the ASPIRE registry. Eur. Respir. J.2013; 41 (6): 1292–1301. DOI: 10.1183/ 09031936.00079512.
(check this in PDF content)
22
Cottin V., Nunes H., Brillet P.Y. et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur. Respir. J.2005; 26 (4): 586–593. DOI: 10. 1183/09031936.05.00021005.
(check this in PDF content)
23
Escribano-Subias P., Blanco I., Lopez-Meseguer M. et al. Survival in pulmonary hypertension in Spain: insights from the Spanish registry.Eur. Respir. J.2012; 40 (3): 596–603. DOI: 10.1183/09031936.00101211.
(check this in PDF content)
24
Pengo V., Lensing A.W., Prins M.H. et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N. Engl. J. Med. 2004; 350 (22): 2257–2264. DOI: 10.1056/NEJMoa032274.
(check this in PDF content)
25
Pepke-Zaba J., Delcroix M., Lang I. et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation. 2011; 124 (18): 1973–1981. DOI: 10.1161/CIRCULATIONAHA.110.015008.
(check this in PDF content)
26
Soubrier F., Chung W.K., Machado R. et al. Genetics and genomics of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 2013; 62 (25, Suppl.): D13–D21.
(check this in PDF content)
27
Ma L., Roman-Campos D., Austin E.D. et al. A novel channelopathy in pulmonary arterial hypertension. N. Engl. J. Med.2013; 369 (4): 351–361. DOI: 10.1056/ NEJMoa1211097.
(check this in PDF content)
28
Eyries M., Montani D., Girerd B. et al. EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nat. Genet. 2014; 46 (1): 65–69. DOI: 10.1038/ng.2844.
(check this in PDF content)
29
Eddahibi S., Chaouat A., Morrell N. et al. Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease. Circulation. 2003; 108 (15): 1839–1844. DOI: 10.1161/ 01.CIR.0000091409.53101.E8.
(check this in PDF content)
30
Bonderman D., Wexberg P., Martischnig A.M. et al. A noninvasive algorithm to exclude pre-capillary pulmonary hypertension. Eur. Respir. J.2011; 37 (5): 1096–1103. DOI: 10.1183/09031936.00089610.
(check this in PDF content)
31
Rich J.D., Thenappan T., Freed B. et al. QTc prolongation is associated with impaired right ventricular function and predicts mortality in pulmonary hypertension. Int. J. Cardiol.2013; 167 (3): 669–676. DOI: 10.1016/j.ijcard. 2012.03.071.
(check this in PDF content)
32
Sun P.Y., Jiang X., Gomberg-Maitland M. et al. Prolonged QRS duration: a new predictor of adverse outcome in idiopathic pulmonary arterial hypertension. Chest. 2012; 141: 374–380.
(check this in PDF content)
33
Olsson K.M., Nickel N.P., Tongers J. et al. Atrial flutter and fibrillation in patients with pulmonary hypertension. Int. J. Cardiol.2013; 167 (5): 2300–2305. DOI: 10.1016/ j.ijcard.2012.06.024.
(check this in PDF content)
34
Rich S., Dantzker D.R., Ayres S.M. et al. Primary pulmonary hypertension: a national prospective study.Ann. Intern. Med. 1987; 107 (2): 216–223.
(check this in PDF content)
35
Milne E.N. Forgotten gold in diagnosing pulmonary hypertension: the plain chest radiograph. Radiographics. 2012; 32 (4): 1085–1087. DOI: 10.1148/rg.324125021.
(check this in PDF content)
36
Trip P., Nossent E.J., de Man F.S. et al. Severely reduced diffusion capacity in idiopathic pulmonary arterial hypertension: patient characteristics and treatment responses. Eur. Respir. J.2013; 42 (6): 1575–1585. DOI: 10.1183/ 09031936.00184412.
(check this in PDF content)
37
Sun X.G., Hansen J.E., Oudiz R.J. et al. Pulmonary function in primary pulmonary hypertension.J. Am. Coll. Cardiol. 2003; 41 (6): 1028–1035.
(check this in PDF content)
38
Hoeper M.M., Pletz M.W., Golpon H. et al. Prognostic value of blood gas analyses in patients with idiopathic pulmonary arterial hypertension. Eur. Respir. J. 2007; 29 (5): 944–950. DOI: 10.1183/09031936.00134506.
(check this in PDF content)
39
Pellegrino R., Viegi G., Brusasco V. et al. Interpretative strategies for lung function tests. Eur. Respir. J.2005; 26 (5): 948–968. DOI: 10.1183/09031936.05.00035205.
(check this in PDF content)
40
Holverda S., Bogaard H.J., Groepenhoff H. et al. Cardiopulmonary exercise test characteristics in patients with chronic obstructive pulmonary disease and associated pulmonary hypertension. Respiration. 2008; 76 (2): 160–167. DOI: 10.1159/000110207.
(check this in PDF content)
41
Jilwan F.N., Escourrou P., Garcia G. et al. High occurrence of hypoxemic sleep respiratory disorders in precapillary pulmonary hypertension and mechanisms. Chest. 2013; 143 (1): 47–55. DOI: 10.1378/chest.11-3124.
(check this in PDF content)
42
Rafanan A.L., Golish J.A., Dinner D.S. et al. Nocturnal hypoxemia is common in primary pulmonary hypertension. Chest. 2001; 120 (3): 894–899.
(check this in PDF content)
43
Rudski L.G., Lai W.W., Afilalo J. et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography.J. Am. Soc. Echocardiogr.2010; 23 (7): 685–713. DOI: 10.1016/j.echo.2010.05.010.
(check this in PDF content)
44
Lang R.M., Badano L.P., Mor-Avi V. et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur. Heart J. Cardiovasc. Imaging. 2015; 16 (3): 233–270. DOI: 10.1093/ehjci/ jev014.
(check this in PDF content)
45
Foale R., Nihoyannopoulos P., McKenna W. et al. Echocardiographic measurement of the normal adult right ventricle. Br. Heart J.1986; 56 (1): 33–44.
(check this in PDF content)
46
Hachulla E., Gressin V., Guillevin L. et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum.2005; 52 (12): 3792–3800. DOI: 10.1002/ art.21433.
(check this in PDF content)
47
Tunariu N., Gibbs S.J.R., Win Z. et al. Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J. Nucl. Med.2007; 48 (5): 680–684. DOI: 10.2967/ jnumed.106.039438.
(check this in PDF content)
48
Meng J.J., Zhang L.J., Wang Q. et al. A comparison of ventilation/perfusion single photon emission CT and CT pulmonary angiography for diagnosis of pulmonary embolism. Zhonghua Jie He He Hu Xi Za Zhi.2013; 36 (3): 177–181. Легочная гипертензия. Диагностика и лечение. Европейские клинические рекомендации (2015) (часть 2-я) 464
(check this in PDF content)
49
Rajaram S., Swift A.J., Telfer A. et al. 3D contrastenhanced lung perfusion MRI is an effective screening tool for chronic thromboembolic pulmonary hypertension: results from the ASPIRE Registry. Thorax. 2013; 68 (7): 677–678. DOI: 10.1136/thoraxjnl-2012-203020.
(check this in PDF content)
50
Rajaram S., Swift A.J., Condliffe R. et al. CT features of pulmonary arterial hypertension and its major subtypes: a systematic CT evaluation of 292 patients from the ASPIRE Registry. Thorax. 2015; 70 (4): 382–387. DOI: 10.1136/thoraxjnl-2014-206088.
(check this in PDF content)
51
Shen Y., Wan C., Tian P. et al. CT-base pulmonary artery measurement in the detection of pulmonary hypertension: a meta-analysis and systematic review. Medicine(Baltimore). 2014; 93 (27): e256. DOI: 10.1097/MD.000000 0000000256.
(check this in PDF content)
52
Tan R.T., Kuzo R., Goodman L.R. et al. Utility of CT scan evaluation for predicting pulmonary hypertension in patients with parenchymal lung disease. Chest. 1998; 113 (5): 1250–1256.
(check this in PDF content)
53
Resten A., Maitre S., Humbert M. et al. Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease. Am. J. Roentgenol. 2004; 183 (1): 65–70. DOI: 10. 2214/ajr.183.1.1830065.
(check this in PDF content)
54
Dartevelle P., Fadel E., Mussot S. et al. Chronic thromboembolic pulmonary hypertension. Eur. Respir. J. 2004; 23 (4): 637–648.
(check this in PDF content)
55
Reichelt A., Hoeper M.M., Galanski M. et al. Chronic thromboembolic pulmonary hypertension: evaluation with 64-detector row CT versus digital substraction angiography. Eur. J. Radiol.2008; 71 (1): 49–54. DOI: 10.1016/ j.ejrad.2008.03.016.
(check this in PDF content)
56
Fedullo P.F., Auger W.R., Kerr K.M. et al. Chronic thromboembolic pulmonary hypertension. N. Engl. J. Med. 2001; 345 (20): 1465–1472. DOI: 10.1056/NEJMra 010902.
(check this in PDF content)
57
Fukui S., Ogo T., Morita Y. et al. Right ventricular reverse remodelling after balloon pulmonary angioplasty. Eur. Respir. J. 2014; 43 (5): 1394–1402. DOI: 10.1183/0903 1936.00012914.
(check this in PDF content)
58
Castaner E., Alguersuari A., Andreu M. et al. Imaging findings in pulmonary vasculitis. Semin. Ultrasound. CT MR. 2012; 33 (6): 567–579. DOI: 10.1053/j.sult.2012.05.001.
(check this in PDF content)
59
Nawaz A., Litt H.I., Stavropoulos S.W. et al. Digital subtraction pulmonary arteriography versus multidetector CT in the detection of pulmonary arteriovenous malformations.J. Vasc. Interv. Radiol. 2008; 19 (11): 1582–1588. DOI: 10.1016/j.jvir.2008.07.011.
(check this in PDF content)
60
Peacock A.J., Vonk Noordegraaf A. Cardiac magnetic resonance imaging in pulmonary arterial hypertension.Eur. Respir. Rev.2013; 22 (130): 526–534. DOI: 10.1183/0905 9180.00006313.
(check this in PDF content)
61
Swift A.J., Rajaram S., Condliffe R. et al. Diagnostic accuracy of cardiovascular magnetic resonance imaging of right ventricular morphology and function in the assessment of suspected pulmonary hypertension results from the ASPIRE registry.J. Cardiovasc. Magn. Reson. 2012; 14: 40–50. DOI: 10.1186/1532-429X-14-40.
(check this in PDF content)
62
Swift A.J., Rajaram S., Hurdman J. et al. Noninvasive estimation of PA pressure, flow, and resistance with CMR imaging: derivation and prospective validation study from the ASPIRE registry. JACC Cardiovasc. Imaging.2013; 6 (10): 1036–1047. DOI: 10.1016/j.jcmg.2013.01.013.
(check this in PDF content)
63
Ley S., Kauczor H.U., Heussel C.P. et al. Value of contrast-enhanced MR angiography and helical CT angiography in chronic thromboembolic pulmonary hypertension. Eur. Radiol.2003; 13 (10): 2365–2371. DOI: 10.1007/ s00330-003-1878-8.
(check this in PDF content)
64
Wolferen S.A., Marcus J.T., Boonstra A. et al. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur. Heart J.2007; 28 (10): 1250–1257. DOI: 10.1093/ eurheartj/ehl477.
(check this in PDF content)
65
Peacock A.J., Crawley S., McLure L. et al. Changes in right ventricular function measured by cardiac magnetic resonance imaging in patients receiving pulmonary arterial hypertension–targeted therapy: the EURO-MR Study. Circ. Cardiovasc. Imaging.2014; 7 (1): 107–114. DOI: 10. 1161/CIRCIMAGING.113.000629.
(check this in PDF content)
66
Veerdonk M.C., Kind T., Marcus J.T. et al. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy.J. Am. Coll. Cardiol.2011; 58 (24): 2511–2519. DOI: 10.1016/ j.jacc.2011.06.068.
(check this in PDF content)
67
Albrecht T., Blomley M.J., Cosgrove D.O. et al. Noninvasive diagnosis of hepatic cirrhosis by transit-time analysis of an ultrasound contrast agent. Lancet. 1999; 353 (9164): 1579–1583. DOI: 10.1016/S0140-6736(98)06373-9.
(check this in PDF content)
68
Naeije R. Hepatopulmonary syndrome and portopulmonary hypertension. Swiss. Med. Wkly.2003; 133 (11-12): 163–169. DOI: 2003/11/smw-10016.
(check this in PDF content)
69
Hoeper M.M., Lee S.H., Voswinckel R. et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J. Am. Coll. Cardiol. 2006; 48 (12): 2546–2552. DOI: 10. 1016/j.jacc.2006.07.061.
(check this in PDF content)
70
Kovacs G., Avian A., Pienn M. et al. Reading pulmonary vascular pressure tracings. How to handle the problems of zero leveling and respiratory swings. Am. J. Respir. Crit. Care Med.2014; 190: 252–257.
(check this in PDF content)
71
Hoeper M.M., Maier R., Tongers J. et al. Determination of cardiac output by the Fick method, thermodilution, and acetylene rebreathing in pulmonary hypertension. Am. J. Respir. Crit. Care Med.1999; 160 (2): 535–541. DOI: 10. 1164/ajrccm.160.2.9811062.
(check this in PDF content)
72
Frost A.E., Farber H.W., Barst R.J. et al. Demographics and outcomes of patients diagnosed with pulmonary hypertension with pulmonary capillary wedge pressures 16 to 18 mm Hg: insights from the REVEAL Registry. Chest. 2013; 143 (1): 185–195. DOI: 10.1378/chest.11-1387.
(check this in PDF content)
73
Abraham W.T., Adamson P.B., Bourge R.C. et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011; 377 (9766): 658–666. DOI: 10.1016/S0140-6736(11) 60101-3.
(check this in PDF content)
74
Prasad A., Hastings J.L., Shibata S. et al. Characterization of static and dynamic left ventricular diastolic function in patients with heart failure with a preserved ejection fraction.Circ. Heart Fail. 2010; 3 (5): 617–626. DOI: 10. 1161/CIRCHEARTFAILURE.109.867044.
(check this in PDF content)
75
Fujimoto N., Borlaug B.A., Lewis G.D. et al. Hemodynamic responses to rapid saline loading: the impact of age, sex, and heart failure. Circulation. 2013; 127 (1): 55–62. DOI: 10.1161/CIRCULATIONAHA.112.111302.
(check this in PDF content)
76
Fox B.D., Shimony A., Langleben D. et al. High prevalence of occult left heart disease in scleroderma-pulmonary hypertension. Eur. Respir. J.2013; 42 (4): 1083–1091. DOI: 10.1183/09031936.00091212.
(check this in PDF content)
77
Robbins I.M., Hemnes A.R., Pugh M.E. et al. High prevalence of occult pulmonary venous hypertension revealed by fluid challenge in pulmonary hypertension. Circ. Heart Fail. 2014; 7 (1): 116–122. DOI: 10.1161/CIRCHEARTFAILURE.113.000468.
(check this in PDF content)
78
Borlaug B.A., Nishimura R.A., Sorajja P. et al. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ. Heart Fail. 2010; 3 (5): 588–595. DOI: 10.1161/CIRCHEARTFAILURE. 109.930701.
(check this in PDF content)
79
Hager W.D., Collins I., Tate J.P. et al. Exercise during cardiac catheterization distinguishes between pulmonary and left ventricular causes of dyspnea in systemic sclerosis patients.Clin. Respir. J. 2013; 7 (3): 227–236. DOI: 10. 1111/j.1752-699X.2012.00310.x.
(check this in PDF content)
80
Halpern S.D., Taichman D.B. Misclassification of pulmonary hypertension due to reliance on pulmonary capillary wedge pressure rather than left ventricular end-diastolic pressure. Chest. 2009; 136 (1): 37–43. DOI: 10. 1378/chest.08-2784.
(check this in PDF content)
81
Naeije R., Vachiery J.L., Yerly P. et al. The transpulmonary pressure gradient for the diagnosis of pulmonary vascular disease. Eur. Respir. J.2013; 41 (1): 217–223. DOI: 10.1183/09031936.00074312.
(check this in PDF content)
82
Provencher S., Herve P., Sitbon O. et al. Changes in exercise haemodynamics during treatment in pulmonary arterial hypertension. Eur. Respir. J.2008; 32 (2): 393–398. DOI: 10.1183/09031936.00009008.
(check this in PDF content)
83
Tedford R.J., Beaty C.A., Mathai S.C. et al. Prognostic value of the pre-transplant diastolic pulmonary artery pressure-to-pulmonary capillary wedge pressure gradient in cardiac transplant recipients with pulmonary hypertension. J. Heart Lung Transplant.2014; 33: 289–297. DOI: 10.1056/NEJM199207093270203.
(check this in PDF content)
84
Rich S., Kaufmann E., Levy P.S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension [see comments]. N. Engl. J. Med. 1992; 327 (2): 76–81.
(check this in PDF content)
85
Sitbon O., Humbert M., Jaїs X., et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005; 111 (23): 3105–3111. DOI: 10.1161/CIRCULATIONAHA.104.488486.
(check this in PDF content)
86
Barst R., McGoon M., Torbicki A. et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 2004; 43 (Suppl. 1): S40–S47.
(check this in PDF content)
87
Morgan J.M., McCormack D.G., Griffiths M.J. et al. Adenosine as a vasodilator in primary pulmonary hypertension [see comments]. Circulation. 1991; 84 (83): 1145–1149.
(check this in PDF content)
88
Nootens M., Schrader B., Kaufmann E. et al. Comparative acute effects of adenosine and prostacyclin in primary pulmonary hypertension. Chest. 1995; 107 (1): 54–57.
(check this in PDF content)
89
Hoeper M.M., Olschewski H., Ghofrani H.A. et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension.J. Am. Coll. Cardiol.2000; 35 (1): 176–182.
(check this in PDF content)
90
Opitz C.F., Wensel R., Bettmann M. et al. Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation. Eur. Heart J.2003; 24: 356–365.
(check this in PDF content)
91
Kim N.H., Delcroix M., Jenkins D.P. et al. Chronic thromboembolic pulmonary hypertension. J. Am. Coll. Cardiol. 2013; 62 (25, Suppl.): D92–D99. DOI: 10.1016/ j.jacc.2013.10.024.
(check this in PDF content)
92
Montani D., Price L.C., Dorfmuller P. et al. Pulmonary veno-occlusive disease.Eur. Respir. J.2009; 33 (1): 189– 200. DOI: 10.1183/09031936.00090608.
(check this in PDF content)
93
He J., Fang W., Lv B. et al. Diagnosis of chronic thromboembolic pulmonary hypertension: comparison of ventilation/perfusion scanning and multidetector computed tomography pulmonary angiography with pulmonary angiography. Nucl. Med. Commun. 2012; 33 (5): 459–463. DOI: 10.1097/MNM.0b013e32835085d9.
(check this in PDF content)
94
Cottin V., Le Pavec J., Prevot G. et al. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome.Eur. Respir. J.2010; 35 (1): 105–111. DOI: 10.1183/09031936.00038709.
(check this in PDF content)
95
Taichman D.B., McGoon M.D., Harhay M.O. et al. Wide variation in clinicians’ assessment of New York Heart Association/World Health Organization functional class in patients with pulmonary arterial hypertension. Mayo Clin. Proc.2009; 84 (7): 586–592. DOI: 10.1016/S0025-6196 (11)60747-7.
(check this in PDF content)
96
Sitbon O., Humbert M., Nunes H. et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.J. Am. Coll. Cardiol. 2002; 40 (4): 780–788.
(check this in PDF content)
97
Nickel N., Golpon H., Greer M. et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur. Respir. J. 2012; 39 (3): 589–596. DOI: 10.1183/09031936.00092311.
(check this in PDF content)
98
Barst R.J., Chung L., Zamanian R.T. et al. Functional class improvement and 3-year survival outcomes in patients with pulmonary arterial hypertension in the REVEAL Registry. Chest. 2013; 144 (1): 160–168. DOI: 10.1378/chest.12-2417.
(check this in PDF content)
99
Benza R.L., Miller D.P., Gomberg-Maitland M. et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and LongTerm Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010; 122 (2): 164–172. DOI: 10.1161/CIRCULATIONAHA.109.898122.
(check this in PDF content)
100
McLaughlin V.V., Sitbon O., Badesch D.B. et al. Survival with first-line bosentan in patients with primary pulmonary hypertension.Eur. Respir. J.2005; 25 (2): 244–249. DOI: 10.1183/09031936.05.00054804.
(check this in PDF content)
101
Sachdev A., Villarraga H.R., Frantz R.P. et al. Right ventricular strain for prediction of survival in patients with pulmonary arterial hypertension. Chest. 2011; 139 (6): 1299–1309. DOI: 10.1378/chest.10-2015.
(check this in PDF content)
102
Raymond R.J., Hinderliter A.L., Willis P.W. et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension.J. Am. Coll. Cardiol. 2002; 39 (7): 1214–1219.
(check this in PDF content)
103
Bustamante-Labarta M., Perrone S., De La Fuente R.L. et al. Right atrial size and tricuspid regurgitation severity predict mortality or transplantation in primary pulmonary hypertension. J. Am. Soc. Echocardiogr.2002; 15 (10, Pt 2): 1160–1164.
(check this in PDF content)
104
Forfia P.R., Fisher M.R., Mathai S.C. et al. Tricuspid annular displacement predicts survival in pulmonary hypertension.Am. J. Respir. Crit. Care Med. 2006; 174 (9): 1034–1041. DOI: 10.1164/rccm.200604-547OC.
(check this in PDF content)
105
Thenappan T., Shah S.J., Rich S. et al. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur. Respir. J. 2010; 35 (5): 1079–1087. DOI: 10.1183/09031936.00072709.
(check this in PDF content)
106
Wensel R., Opitz C.F., Anker S.D. et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circula' tion. 2002; 106 (3): 319–324.
(check this in PDF content)
107
McLaughlin V.V., Shillington A., Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002; 106 (12): 1477–1482.
(check this in PDF content)
108
Fine N.M., Chen L., Bastiansen P.M. et al. Outcome prediction by quantitative right ventricular function assessЛегочная гипертензия. Диагностика и лечение. Европейские клинические рекомендации (2015) (часть 2-я) 466 ment in 575 subjects evaluated for pulmonary hypertension.Circ. Cardiovasc. Imaging.2013; 6 (5): 711–721. DOI: 10.1161/CIRCIMAGING.113.000640.
(check this in PDF content)
109
Shimada Y.J., Shiota M., Siegel R.J. et al. Accuracy of right ventricular volumes and function determined by three-dimensional echocardiography in comparison with magnetic resonance imaging: a meta-analysis study. J. Am. Soc. Echocardiogr.2010; 23 (9): 943–953. DOI: 10.1016/ j.echo.2010.06.029.
(check this in PDF content)
110
Smith B.C., Dobson G., Dawson D. et al. Three-dimensional speckle tracking of the right ventricle: toward optimal quantification of right ventricular dysfunction in pulmonary hypertension. J. Am. Coll. Cardiol.2014; 64 (1): 41–51. DOI: 10.1016/j.jacc.2014.01.084.
(check this in PDF content)
111
Grunig E., Tiede H., Enyimayew E.O. et al. Assessment and prognostic relevance of right ventricular contractile reserve in patients with severe pulmonary hypertension. Circulation. 2013; 128 (18): 2005–2015. DOI: 10.1161/ CIRCULATIONAHA.113.001573.
(check this in PDF content)
112
Swift A.J., Rajaram S., Marshall H. et al. Black blood MRI has diagnostic and prognostic value in the assessment of patients with pulmonary hypertension.Eur. Radiol. 2012; 22 (3): 695–702. DOI: 10.1007/s00330-011-2306-0.
(check this in PDF content)
113
Swift A.J., Rajaram S., Campbell M.J. et al. Prognostic value of cardiovascular magnetic resonance imaging measurements corrected for age and sex in idiopathic pulmonary arterial hypertension. Circ. Cardiovasc. Imaging. 2014; 7 (1): 100–106. DOI: 10.1161/CIRCIMAGING. 113.000338.
(check this in PDF content)
114
Sitbon O., McLaughlin V.V., Badesch D.B. et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax. 2005; 60 (12): 1025–1030. DOI: 10.1136/thx.2005.040618.
(check this in PDF content)
115
Rich J.D., Archer S.L., Rich S. Noninvasive cardiac output measurements in patients with pulmonary hypertension. Eur. Respir. J.2013; 42 (1): 125–133. DOI: 10.1183/ 09031936.00102212.
(check this in PDF content)
116
Savarese G., Paolillo S., Costanzo P. et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. J. Am. Coll. Cardiol.2012; 60 (13): 1192–1201. DOI: 10.1016/j.jacc.2012.01.083.
(check this in PDF content)
117
Gabler N.B., French B., Strom B.L. et al. Validation of 6minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. Circulation. 2012; 126 (3): 349–356. DOI: 10.1161/CIRCULATIONAHA.112. 105890.
(check this in PDF content)
118
Fritz J.S., Blair C., Oudiz R.J. et al. Baseline and followup 6-min walk distance and brain natriuretic peptide predict 2-year mortality in pulmonary arterial hypertension. Chest. 2013; 143 (2): 315–323. DOI: 10.1378/chest.120270.
(check this in PDF content)
119
Paciocco G., Martinez F., Bossone E. et al. Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. Eur. Respir. J. 2001; 17 (4): 647–652.
(check this in PDF content)
120
Provencher S., Chemla D., Herve P. et al. Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension. Eur. Respir. J. 2006; 27 (1): 114– 120. DOI: 10.1183/09031936.06.00042705.
(check this in PDF content)
121
Sun X.G., Hansen J.E., Oudiz R.J. et al. Exercise pathophysiology in patients with primary pulmonary hypertension. Circulation. 2001; 104 (4): 429–435.
(check this in PDF content)
122
Wensel R., Francis D.P., Meyer F.J. et al. Incremental prognostic value of cardiopulmonary exercise testing and resting haemodynamics in pulmonary arterial hypertension. Int. J. Cardiol. 2013; 167 (4): 1193–1198. DOI: 10. 1016/j.ijcard.2012.03.135.
(check this in PDF content)
123
Blumberg F.C., Arzt M., Lange T. et al. Impact of right ventricular reserve on exercise capacity and survival in patients with pulmonary hypertension. Eur. J. Heart Fail. 2013; 15 (7): 771–775. DOI: 10.1093/eurjhf/hft044.
(check this in PDF content)
124
Diller G.P., Dimopoulos K., Okonko D. et al. Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication. Circula' tion. 2005; 112 (6): 828–835. DOI: 10.1161/CIRCULATIONAHA.104.529800.
(check this in PDF content)
125
Arena R., Lavie C.J., Milani R.V. et al. Cardiopulmonary exercise testing in patients with pulmonary arterial hypertension: an evidence-based review. J. Heart Lung Transplant.2010; 29 (2): 159–173. DOI: 10.1016/j.healun. 2009.09.003.
(check this in PDF content)
126
Pullamsetti S., Kiss L., Ghofrani H.A. et al. Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension. FASEB J. 2005; 19 (9): 1175–1177. DOI: 10.1096/fj.04-3223fje.
(check this in PDF content)
127
Kielstein J.T., Bode-Boger S.M., Hesse G. et al. Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. Arterioscler. Thromb. Vasc. Biol.2005; 25 (7): 1414–1418. DOI: 10.1161/01.ATV.0000168414. 06853.f0.
(check this in PDF content)
128
Kielstein J.T., Impraim B., Simmel S. et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation. 2004; 109 (2): 172–177. DOI: 10.1161/01.CIR.00001 05764.22626.B1.
(check this in PDF content)
129
Kawut S.M., Horn E.M., Berekashvili K.K. et al. von Willebrand factor independently predicts long-term survival in patients with pulmonary arterial hypertension. Chest. 2005; 128 (4): 2355–2362. DOI: 10.1378/chest. 128.4.2355.
(check this in PDF content)
130
Kümpers P., Nickel N., Lukasz A. et al. Circulating angiopoietins in idiopathic pulmonary arterial hypertension.Eur. Heart J.2010; 31 (18): 2291–2300. DOI: 10. 1093/eurheartj/ehq226.
(check this in PDF content)
131
Rubens C., Ewert R., Halank M. et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest. 2001; 120 (5): 1562–1569.
(check this in PDF content)
132
Quarck R., Nawrot T., Meyns B. et al. C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension. J. Am. Coll. Cardiol.2009; 53 (14): 1211– 1218. DOI: 10.1016/j.jacc.2008.12.038.
(check this in PDF content)
133
Balabanian K., Foussat A., Dorfmuller P. et al. CX(3)C chemokine fractalkine in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med.2002; 165 (10): 1419–1425. DOI: 10.1164/rccm.2106007.
(check this in PDF content)
134
Dorfmuller P., Zarka V., Durand-Gasselin I. et al. Chemokine RANTES in severe pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2002; 165 (4): 534–539. DOI: 10.1164/ajrccm.165.4.2012112.
(check this in PDF content)
135
Humbert M., Monti G., Brenot F. et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am. J. Respir. Crit. Care Med.1995; 151 (5): 1628–1631. DOI: 10.1164/ajrccm. 151.5.7735624.
(check this in PDF content)
136
Nagaya N., Nishikimi T., Uematsu M. et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation. 2000; 102 (8): 865–870.
(check this in PDF content)
137
Leuchte H.H., El Nounou M., Tuerpe J.C. et al. N-terminal pro-brain natriuretic peptide and renal insufficiency as predictors of mortality in pulmonary hypertension. Chest. 2007; 131 (2): 402–409. DOI: 10.1378/chest.06-1758.
(check this in PDF content)
138
Fijalkowska A., Kurzyna M., Torbicki A. et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest. 2006; 129 (5): 1313–1321. DOI: 10.1378/chest.129.5. 1313.
(check this in PDF content)
139
Torbicki A., Kurzyna M., Kuca P. et al. Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation. 2003; 108 (7): 844–848. DOI: 10.1161/ 01.CIR.0000084544.54513.E2.
(check this in PDF content)
140
Nickel N., Kempf T., Tapken H. et al. Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2008; 178 (5): 534– 541. DOI: 10.1164/rccm.200802-235OC.
(check this in PDF content)
141
Nagaya N., Uematsu M., Satoh T. et al. Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension.Am. J. Respir. Crit. Care Med. 1999; 160 (2): 487–492. DOI: 10.1164/ajrccm.160. 2.9812078.
(check this in PDF content)
142
Lorenzen J.M., Nickel N., Kramer R. et al. Osteopontin in patients with idiopathic pulmonary hypertension. Chest. 2011; 139 (5): 1010–1017. DOI: 10.1378/chest.10-1146.
(check this in PDF content)
143
Warwick G., Thomas P.S., Yates D.H. Biomarkers in pulmonary hypertension. Eur. Respir. J.2008; 32 (2): 503– 512. DOI: 10.1183/09031936.00160307.
(check this in PDF content)
144
Hoeper M.M., Markevych I., Spiekerkoetter E. et al. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur. Respir. J. 2005; 26 (5): 858–863. DOI: 10.1183/09031936.05.00075305.
(check this in PDF content)
145
McLaughlin V.V., Gaine S.P., Howard L.S. et al. Treatment goals of pulmonary hypertension.J. Am. Coll. Cardiol.2013; 62 (25, Suppl.): D73–D81.
(check this in PDF content)
146
GalièN., Manes A., Negro L. et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur. Heart J. 2009; 30 (4): 394–403. DOI: 10. 1093/eurheartj/ehp022.
(check this in PDF content)
147
Bai Y., Sun L., Hu S. et al. Combination therapy in pulmonary arterial hypertension: a meta-analysis. Cardiology. 2011; 120 (3): 157–165. DOI: 10.1159/000334431.
(check this in PDF content)
148
GalièN., Simonneau G. The Fifth World Symposium on Pulmonary Arterial Hypertension.J. Am. Coll. Cardiol. 2013; 62 (Suppl.): D1–D3.
(check this in PDF content)
149
GalièN., Corris P., Frost A. et al. Updated treatment algorithm of pulmonary hypertension.J. Am. Coll. Cardiol. 2013; 62 (Suppl.): D60–D72.
(check this in PDF content)
150
Löwe B., Gräfe K., Ufer C. et al. Anxiety and depression in patients with pulmonary hypertension. Psychosom. Med. 2004; 66 (6): 831–836. DOI: 10.1097/01.psy.0000145593. 37594.39.
(check this in PDF content)
151
GalièN., Hoeper M., Humbert M. et al. Guidelines on diagnosis and treatment of pulmonary hypertension: the Task Force on Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology and of the European Respiratory Society.Eur. Heart J. 2009; 30 (20): 2493–2537. DOI: 10.1093/eurheartj/ehp297.
(check this in PDF content)
152
Mereles D., Ehlken N., Kreuscher S. et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation. 2006; 114 (14): 1482–1489. DOI: 10. 1161/CIRCULATIONAHA.106.618397.
(check this in PDF content)
153
Man F.S., Handoko M.L., Groepenhoff H. et al. Effects of exercise training in patients with idiopathic pulmonary arterial hypertension. Eur. Respir. J.2009; 34 (3): 669–675. DOI: 10.1183/09031936.00027909.
(check this in PDF content)
154
Grunig E., Ehlken N., Ghofrani A. et al. Effect of exercise and respiratory training on clinical progression and survival in patients with severe chronic pulmonary hypertension. Respiration. 2011; 81 (5): 394–401. DOI: 10.1159/ 000322475.
(check this in PDF content)
155
Grunig E., Maier F., Ehlken N. et al. Exercise training in pulmonary arterial hypertension associated with connective tissue diseases.Arthritis Res. Ther.2012; 14 (3): R148. DOI: 10.1186/ar3883.
(check this in PDF content)
156
Grunig E., Lichtblau M., Ehlken N. et al. Safety and efficacy of exercise training in various forms of pulmonary hypertension.Eur. Respir. J. 2012; 40 (1): 84–92. DOI: 10.1183/09031936.00123711.
(check this in PDF content)
157
Becker-Grunig T., Klose H., Ehlken N. et al. Efficacy of exercise training in pulmonary arterial hypertension associated with congenital heart disease.Int. J. Cardiol. 2013; 168 (1): 375–381. DOI: 10.1016/j.ijcard.2012.09.036.
(check this in PDF content)
158
Weinstein A.A., Chin L.M.K., Keyser R.E. et al. Effect of aerobic exercise training on fatigue and physical activity in patients with pulmonary arterial hypertension. Respir. Med.2013; 107 (5): 778–784. DOI: 10.1016/j.rmed.2013. 02.006.
(check this in PDF content)
159
Chan L., Chin L.M., Kennedy M. et al. Benefits of intensive treadmill exercise training on cardiorespiratory function and quality of life in patients with pulmonary hypertension. Chest. 2013; 143 (2): 333–343. DOI: 10.1378/ chest.12-0993.
(check this in PDF content)
160
Jaїs X., Olsson K.M., Barbera J.A. et al. Pregnancy outcomes in pulmonary arterial hypertension in the modern management era.Eur. Respir. J.2012; 40 (4): 881–885. DOI: 10.1183/09031936.00141211.
(check this in PDF content)
161
Duarte A.G., Thomas S., Safdar Z. et al. Management of pulmonary arterial hypertension during pregnancy: a retrospective, multicenter experience. Chest. 2013; 143 (5): 1330–1336. DOI: 10.1378/chest.12-0528.
(check this in PDF content)
162
Thorne S., Nelson-Piercy C., MacGregor A.J. et al. Pregnancy and contraception in heart disease and pulmonary arterial hypertension.J. Fam. Plann. Reprod. Health Care. 2006; 32 (2): 75–81. DOI: 10.1783/147118906776276486.
(check this in PDF content)
163
Bendayan D., Hod M., Oron G. et al. Pregnancy outcome in patients with pulmonary arterial hypertension receiving prostacyclin therapy. Obstet. Gynecol. 2005; 106 (5, Pt 2): 1206–1210. DOI: 10.1097/01.AOG.0000164074.64137.f1.
(check this in PDF content)
164
Bonnin M., Mercier F.J., Sitbon O. et al. Severe pulmonary hypertension during pregnancy: mode of delivery and anesthetic management of 15 consecutive cases. Anesthesiology. 2005; 102 (6): 1133–1137.
(check this in PDF content)
165
Meyer S., McLaughlin V.V., Seyfarth H.J. et al. Outcomes of noncardiac, nonobstetric surgery in patients with PAH: an international prospective survey.Eur. Respir. J. 2013; 41 (6): 1302–1307. DOI: 10.1183/09031936.00089212.
(check this in PDF content)
166
Olofsson C., Bremme K., Forssell G. et al. Cesarean section under epidural ropivacaine 0.75% in a parturient with severe pulmonary hypertension. Acta. Anaesthesiol. Scand. 2001; 45 (2): 258–260.
(check this in PDF content)
167
Raines D.E., Liberthson R.R., Murray J.R. Anesthetic management and outcome following noncardiac surgery in nonparturients with Eisenmenger’s physiology.J. Clin. Anesth. 1996; 8 (5): 341–347.
(check this in PDF content)
168
Guillevin L., Armstrong I., Aldrighetti R. et al. Understanding the impact of pulmonary arterial hypertension on patients’ and carers’ lives. Eur. Respir. Rev.2013; 22 (130): 535–542. DOI: 10.1183/09059180.00005713. Легочная гипертензия. Диагностика и лечение. Европейские клинические рекомендации (2015) (часть 2-я) 468
(check this in PDF content)
169
Weitzenblum E., Sautegeau A., Ehrhart M. et al. Longterm oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 1985; 131 (4): 493–498. DOI: 10.1164/arrd.1985.131.4.493.
(check this in PDF content)
170
Frydman N., Steffann J., Girerd B. et al. Pre-implantation genetic diagnosis in pulmonary arterial hypertension due to BMPR2 mutation. Eur. Respir. J.2012; 39 (6): 1534–1535. DOI: 10.1183/09031936.00185011.
(check this in PDF content)
171
Fuster V., Steele P.M., Edwards W.D. et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation. 1984; 70 (4): 580–587.
(check this in PDF content)
172
Herve P., Humbert M., Sitbon O. et al. Pathobiology of pulmonary hypertension: the role of platelets and thrombosis. Clin. Chest Med.2001 (3); 22: 451–458.
(check this in PDF content)
173
Hoeper M.M., Sosada M., Fabel H. Plasma coagulation profiles in patients with severe primary pulmonary hypertension.Eur. Respir. J.1998; 12 (6): 1446–1449.
(check this in PDF content)
174
Huber K., Beckmann R., Frank H. et al. Fibrinogen, t-PA, and PAI-1 plasma levels in patients with pulmonary hypertension. Am. J. Respir. Crit. Care Med.1994; 150 (4): 929–933. DOI: 10.1164/ajrccm.150.4.7921465.
(check this in PDF content)
175
Olsson K.M., Delcroix M., Ghofrani H.A. et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation. 2014; 129 (1): 57–65. DOI: 10.1161/CIRCULATIONAHA.113.004526.
(check this in PDF content)
176
GalièN., Delcroix M., Ghofrani A. et al. Anticoagulant therapy does not influence long-term outcomes in patients with pulmonary arterial hypertension (PAH): insights from the randomised controlled SERAPHIN trial of macitentan. Eur. Heart J. 2014; 35: 10–12.
(check this in PDF content)
177
Preston R.J., Roberts K.E., Miller D.P. et al. Effect of warfarin treatment on survival of patients with pulmonaryarterial hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL). Am. J. Respir. Crit. Care Med. 2014; 189: A2464.
(check this in PDF content)
178
Cohn J.N. Optimal diuretic therapy for heart failure.Am. J. Med.2001; 111 (7): 577.
(check this in PDF content)
179
Sandoval J., Aguirre J.S., Pulido T. et al. Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. Am. J. Respir. Crit. Care Med. 2001; 164 (9): 1682–1687. DOI: 10.1164/ajrccm.164.9.2106076.
(check this in PDF content)
180
Rich S., Seidlitz M., Dodin E. et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest. 1998; 114 (3): 787–792.
(check this in PDF content)
181
Ruiter G., Lankhorst S., Boonstra A. et al. Iron deficiency is common in idiopathic pulmonary arterial hypertension. Eur. Respir.J. 2011; 37: 1386–1391.
(check this in PDF content)
182
Ruiter G., Lanser I.J., de Man F.S. et al. Iron deficiency in systemic sclerosis patients with and without pulmonary hypertension. Rheumatology(Oxford). 2014; 53 (2): 285–292. DOI: 10.1093/rheumatology/ket331.
(check this in PDF content)
183
Broberg C.S., Bax B.E., Okonko D.O. et al. Blood viscosity and its relationship to iron deficiency, symptoms, and exercise capacity in adults with cyanotic congenital heart disease.J. Am. Coll. Cardiol.2006; 48 (2): 356–365. DOI: 10.1016/j.jacc.2006.03.040.
(check this in PDF content)
184
Rhodes C.J., Howard L.S., Busbridge M. et al. Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension clinical prevalence, outcomes, and mechanistic insights. J. Am. Coll. Cardiol.2011; 58 (3): 300– 309. DOI: 10.1016/j.jacc.2011.02.057.
(check this in PDF content)
185
Bruaene A., Delcroix M., Pasquet A. et al. Iron deficiency is associated with adverse outcome in Eisenmenger patients. Eur. Heart J. 2011; 32 (22): 2790–2799. DOI: 10.1093/eurheartj/ehr130.
(check this in PDF content)
186
Viethen T., Gerhardt F., Dumitrescu D. et al. Ferric carboxymaltose improves exercise capacity and quality of life in patients with pulmonary arterial hypertension and iron deficiency: a pilot study.Int. J. Cardiol. 2014; 175 (2): 233–239. DOI: 10.1016/j.ijcard.2014.04.233.
(check this in PDF content)
187
GalièN., Ussia G., Passarelli P. et al. Role of pharmacologic tests in the treatment of primary pulmonary hypertension. Am. J. Cardiol. 1995; 75 (3): 55A–62A.
(check this in PDF content)
188
Mukerjee D., St. George D., Coleiro B. et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann. Rheum. Dis.2003; 62 (11): 1088–1093.
(check this in PDF content)
189
Montani D., Savale L., Natali D. et al. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension.Eur. Heart J. 2010; 31 (15): 1898–1907. DOI: 10.1093/eurheartj/ehq170.
(check this in PDF content)
190
Giaid A., Yanagisawa M., Langleben D. et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.N. Engl. J. Med.1993; 328 (4): 1732–1739. DOI: 10.1056/NEJM199306173282402.
(check this in PDF content)
191
Stewart D.J., Levy R.D., Cernacek P. et al. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann. Intern. Med.1991; 114 (6): 464–469.
(check this in PDF content)
192
GalièN., Manes A., Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc. Res. 2004; 61 (2): 227–237.
(check this in PDF content)
193
GalièN., Badesch B.D., Oudiz R. et al. Ambrisentan therapy for pulmonary arterial hypertension. J. Am. Coll. Cardiol.2005; 46 (3): 529–535. DOI: 10.1016/j.jacc.2005. 04.050.
(check this in PDF content)
194
GalièN., Olschewski H., Oudiz R.J. et al. Ambrisentan for the treatment of pulmonary arterial hypertension. Results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008; 117 (23): 3010–3019. DOI: 10.1161/CIRCULATIONAHA. 107.742510.
(check this in PDF content)
195
McGoon M., Frost A., Oudiz R. et al. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest. 2009; 135 (1): 122–129. DOI: 10.1378/chest.08-1028.
(check this in PDF content)
196
Channick R.N., Simonneau G., Sitbon O. et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001; 358 (9288): 1119–1123. DOI: 10.1016/S0140-6736(01)06250-X.
(check this in PDF content)
197
Rubin L.J., Badesch D.B., Barst R.J. et al. Bosentan therapy for pulmonary arterial hypertension.N. Engl. J. Med. 2002; 346 (12): 896–903. DOI: 10.1056/NEJMoa012212.
(check this in PDF content)
198
Humbert M., Barst R.J., Robbins I.M. et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur. Respir. J. 2004; 24 (3): 353–359. DOI: 10.1183/09031936.04.00028404.
(check this in PDF content)
199
GalièN., Rubin L.J., Hoeper M. et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008; 371 (9630): 2093–2100. DOI: 10.1016/S0140-6736(08)60919-8.
(check this in PDF content)
200
GalièN., Beghetti M., Gatzoulis M.A. et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006; 114 (1): 48–54. DOI: 10.1161/ CIRCULATIONAHA.106.630715.
(check this in PDF content)
201
Pulido T., Adzerikho I., Channick R.N. et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension.N. Engl. J. Med. 2013; 369 (9): 809–818. DOI: 10.1056/NEJMoa1213917.
(check this in PDF content)
202
Wharton J., Strange J.W., Moller G.M.O. et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells.Am. J. Respir. Crit. Care Med.2005; 172 (1): 105–113. DOI: 10.1164/rccm. 200411-1587OC.
(check this in PDF content)
203
Tantini B., Manes A., Fiumana E. et al. Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Basic. Res. Cardiol. 2005; 100 (2): 131–138. DOI: 10.1007/s00395-004-0504-5.
(check this in PDF content)
204
Ghofrani H.A., Voswinckel R., Reichenberger F. et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.J. Am. Coll. Cardiol.2004; 44 (7): 1488–1496. DOI: 10.1016/j.jacc.2004.06.060.
(check this in PDF content)
205
GalièN., Ghofrani H.A., Torbicki A. et al. the Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med.2005; 353 (20): 2148–2157. DOI: 10.1056/NEJMoa050010.
(check this in PDF content)
206
Sastry B.K.S., Narasimhan C., Reddy N.K. et al. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J. Am. Coll. Cardiol. 2004; 43 (7): 1149–1153. DOI: 10.1016/j.jacc.2003.10.056.
(check this in PDF content)
207
Iversen K., Jensen A.S., Jensen T.V. et al. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. Eur. Heart J.2010; 31 (9): 1124–1131. DOI: 10. 1093/eurheartj/ehq011.
(check this in PDF content)
208
Singh T., Rohit M., Grover A. et al. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension.Am. Heart J.2006; 151 (4): 851.e1–851.e5. DOI: 10.1016/j.ahj.2005.09.006.
(check this in PDF content)
209
Simonneau G., Rubin L., GalièN. et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension.Ann. Intern. Med. 2008; 149 (8): 521–530.
(check this in PDF content)
210
Vachiery J.L., Huez S., Gillies H. et al. Safety, tolerability and pharmacokinetics of an intravenous bolus of sildenafil in patients with pulmonary arterial hypertension. Br. J. Clin. Pharmacol.2011; 71 (2): 289–292. DOI: 10.1111/j. 1365-2125.2010.03831.x.
(check this in PDF content)
211
GalièN., Brundage B.H., Ghofrani H.A. et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009; 119 (22): 2894–2903. DOI: 10.1161/CIRCULATIONAHA.108.839274.
(check this in PDF content)
212
Jing Z.C., Yu Z.X., Shen J.Y. et al. Vardenafil in pulmonary arterial hypertension: a randomized, doubleblind, placebo-controlled study. Am. J. Respir. Crit. Care Med.2011; 183 (12): 1723–1729. DOI: 10.1164/rccm. 201101-0093OC.
(check this in PDF content)
213
Giaid A., Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 1995; 333 (4):
(check this in PDF content)
214
221. DOI: 10.1056/NEJM199507273330403. 214. Ghofrani H.A., GalièN., Grimminger F. et al. Riociguat for the treatment of pulmonary arterial hypertension. N. Engl. J. Med.2013; 369 (4): 330–340. DOI: 10.1056/ NEJMoa1209655.
(check this in PDF content)
215
GalièN., Muller K., Scalise A.V. et al. PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in PAH. Eur. Respir. J.2015; 45 (5): 1314–1322. DOI: 10.1183/09031936.00105914.
(check this in PDF content)
216
Jones D.A., Benjamin C.W., Linseman D.A. Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades. Mol. Pharmacol. 1995; 48 (5): 890–896.
(check this in PDF content)
217
GalièN., Manes A., Branzi A. Prostanoids for pulmonary arterial hypertension. Am. J. Respir. Med.2003; 2 (2): 123–137.
(check this in PDF content)
218
GalièN., Humbert M., Vachiery J.L. et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomised, double-blind placebo-controlled trial. J. Am. Coll. Cardiol. 2002; 39 (9): 1496–1502.
(check this in PDF content)
219
Barst R.J., McGoon M., McLaughlin V.V. et al. Beraprost therapy for pulmonary arterial hypertension. J. Am. Coll. Cardiol. 2003; 41 (12): 2119–2125.
(check this in PDF content)
220
Rubin L.J., Mendoza J., Hood M. et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial.Ann. Intern. Med.1990; 112 (7): 485–491. DOI: 10.7326/0003-4819-112-7-485.
(check this in PDF content)
221
Barst R.J., Rubin L.J., Long W.A. et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N. Engl. J. Med.1996; 334 (5): 296–302. DOI: 10.1056/NEJM199602013340504.
(check this in PDF content)
222
Badesch D.B., Tapson V.F., McGoon M.D. et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial.Ann. Intern. Med.2000; 132 (6): 425–434.
(check this in PDF content)
223
Rosenzweig E.B., Kerstein D., Barst R.J. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation. 1999; 99 (14): 1858–1865.
(check this in PDF content)
224
Krowka M.J., Frantz R.P., McGoon M.D. et al. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension. Hepa' tology. 1999; 30 (3): 641–648. DOI: 10.1002/hep.5103 00307.
(check this in PDF content)
225
Nunes H., Humbert M., Sitbon O. et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension.Am. J. Respir. Crit. Care Med.2003; 167 (10): 1433–1439. DOI: 10.1164/rccm. 200204-330OC.
(check this in PDF content)
226
Cabrol S., Souza R., Jaїs X. et al. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension. J. Heart Lung. Transplant.2007; 26 (4): 357–362. DOI: 10.1016/j.healun.2006.12.014.
(check this in PDF content)
227
Doran A.K., Ivy D.D., Barst R.J. et al. Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension. Int. J. Clin. Pract. Suppl. 2008; 62 (160): 5–9. DOI: 10.1111/j.1742-1241.2008.01811.x.
(check this in PDF content)
228
Sitbon O., Delcroix M., Bergot E. et al. EPITOME-2: an open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulЛегочная гипертензия. Диагностика и лечение. Европейские клинические рекомендации (2015) (часть 2-я) 470 monary arterial hypertension. Am. Heart J. 2014; 167 (2): 210–217. DOI: 10.1016/j.ahj.2013.08.007.
(check this in PDF content)
229
Olschewski H., Simonneau G., GalièN. et al. Inhaled iloprost in severe pulmonary hypertension. N. Engl. J. Med. 2002; 347 (5): 322–329. DOI: 10.1056/NEJMoa020204.
(check this in PDF content)
230
McLaughlin V.V., Oudiz R.J., Frost A. et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med.2006; 174 (11): 1257–1263. DOI: 10.1164/rccm. 200603-358OC.
(check this in PDF content)
231
Hoeper M., Leuchte H., Halank M. et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur. Respir. J. 2006; 28 (4): 691–694. DOI: 10.1183/09031936.06.00057906.
(check this in PDF content)
232
Higenbottam T., Butt A.Y., McMahon A. et al. Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart. 1998; 80 (2): 151–155.
(check this in PDF content)
233
Simonneau G., Barst R.J., GalièN. et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. A double-blind, randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 2002; 165 (6): 800–804. DOI: 10.1164/ajrccm.165.6.2106079.
(check this in PDF content)
234
Hiremath J., Thanikachalam S., Parikh K. et al. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. J. Heart Lung Trans' plant.2010; 29 (2): 137–149. DOI: 10.1016/j.healun. 2009.09.005.
(check this in PDF content)
235
Tapson V.F., Gomberg-Maitland M., McLaughlin V.V. et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, openlabel, 12-week trial. Chest. 2006; 129 (3): 683–688. DOI: 10.1378/chest.129.3.683.
(check this in PDF content)
236
Sitbon O., Manes A., Jaїs X. et al. Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension.J. Cardio' vasc. Pharmacol.2007; 49 (1): 1–5. DOI: 10.1097/FJC. 0b013e31802b3184.
(check this in PDF content)
237
McLaughlin V., Rubin L., Benza R.L. et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.J. Am. Coll. Cardiol.2010; 55 (18): 1915–1922. DOI: 10.1016/ j.jacc.2010.01.027.
(check this in PDF content)
238
Tapson V.F., Torres F., Kermeen F. et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest. 2012; 142 (6): 1383–1390. DOI: 10.1378/chest.11-2212.
(check this in PDF content)
239
Tapson V.F., Jing Z.C., Xu K.F. et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Chest. 2012;142 (6): 1383–1390. DOI: 10.1378/chest.112212.
(check this in PDF content)
240
Jing Z.C., Parikh K., Pulido T. et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation. 2013; 127 (5): 624–633. DOI: 10.1161/ CIRCULATIONAHA.112.124388.
(check this in PDF content)
241
Simonneau G., Torbicki A., Hoeper M.M. et al. Selexipag, an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur. Respir. J. 2012; 40 (4): 874–880. DOI: 10.1183/09031936.0013 7511.
(check this in PDF content)
242
Chen S.L., Zhang F.F., Xu J. et al. Pulmonary artery denervation to treat pulmonary arterial hypertension: the single-center, prospective, first-in-man PADN-1 study (firstin-man pulmonary artery denervation for treatment of pulmonary artery hypertension). J. Am. Coll. Cardiol. 2013; 62 (12): 1092–1100. DOI: 10.1016/j.jacc.2013.05.075.
(check this in PDF content)
243
GalièN., Manes A. New treatment strategies for pulmonary arterial hypertension: hopes or hypes?J. Am. Coll. Cardiol.2013; 62 (12): 1101–1102. DOI: 10.1016/j.jacc. 2013.06.032.
(check this in PDF content)
244
GalièN., Palazzini M., Manes A. Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses. Eur. Heart J.2010; 31 (17): 2080–2086. DOI: 10.1093/eurheartj/ehq152.
(check this in PDF content)
245
Kemp K., Savale L., O’Callaghan D.S. et al. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. J. Heart Lung Transplant.2012; 31 (2): 150–158. DOI: 10.1016/j.healun.2011.11.002.
(check this in PDF content)
246
Sitbon O., Jaїs X., Savale L. et al. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur. Respir. J.2014; 43 (6): 1691–1697. DOI: 10.1183/09031936.00116313.
(check this in PDF content)
247
GalièN., Barbera J.A., Frost A. et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.N. Engl. J. Med.2015; 379: 834–844. DOI: 10.1056/NEJMoa1413687.
(check this in PDF content)
248
McLaughlin V.V., Channick R., Chin K.M. et al. Effect of selexipag on morbidity/mortality in pulmonary arterial hypertension: results of the GRIPHON study. J. Am. Coll. Cardiol.2015; 65 (Suppl. A): A380.
(check this in PDF content)
249
Badesch B.D., Feldman J., Keogh A. et al. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension.Cardiovasc. Ther.2012; 30 (2): 93–99. DOI: 10.1111/j.1755-5922.2011.00279.x.
(check this in PDF content)
250
Provencher S., Sitbon O., Humbert M. et al. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension.Eur. Heart J.2006; 27 (5): 589–595. DOI: 10.1093/eurheartj/ehi728.
(check this in PDF content)
251
McLaughlin V., Channick R.N., Ghofrani H.A. et al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur. Respir. J.2015; 46 (2): 405–413. DOI: 10.1183/13993003.02044-2014.
(check this in PDF content)
252
Dardi F., Manes A., Palazzini M. et al. Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: real-world insights. Eur. Respir. J.2015; 46 (2): 414–421. DOI: 10.1183/09031936. 00209914.
(check this in PDF content)
253
Sandoval J., Gaspar J., Pulido T. et al. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment. J. Am. Coll. Cardiol. 1998; 32: 297–304.
(check this in PDF content)
254
Kurzyna M., Dabrowski M., Bielecki D. et al. Atrial septostomy in treatment of end-stage right heart failure in Patients with pulmonary hypertension. Chest. 2007; 131 (4): 977–983. DOI: 10.1378/chest.06-1227.
(check this in PDF content)
255
Althoff T.F., Knebel F., Panda A. et al. Long-term followup of a fenestrated Amplatzer atrial septal occluder in pulmonary arterial hypertension. Chest. 2008; 133 (1): 283–285. DOI: 10.1378/chest.07-1222.
(check this in PDF content)
256
Keogh A., Benza R.L., Corris P. et al. Interventional and surgical modalities of treatment in pulmonary arterial hypertension. J. Am. Coll. Cardiol.2009; 54 (Suppl.): S67–S77.
(check this in PDF content)
257
Sztrymf B., Souza R., Bertoletti I. et al. Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension.Eur. Respir. J.2010; 35 (6): 1286–1293. DOI: 10.1183/09031936.00070209.
(check this in PDF content)
258
Zamanian R.T., Haddad F., Doyle R.L. et al. Management strategies for patients with pulmonary hypertension in the intensive care unit.Crit. Care Med.2007; 35 (9): 2037–2050.
(check this in PDF content)
259
Price L.C., Wort S.J., Finney S.J. et al. Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review.Crit. Care.2010; 14 (5): R169. DOI: 10.1186/cc9264.
(check this in PDF content)
260
Hoeper M.M., Granton J. Intensive care unit management of patients with severe pulmonary hypertension and right heart failure.Am. J. Respir. Crit. Care Med.2011; 184 (10): 1114–1124. DOI: 10.1164/rccm.201104-0662CI.
(check this in PDF content)
261
Rosenzweig E.B., Brodie D., Abrams D.C. et al. Extracorporeal membrane oxygenation as a novel bridging strategy for acute right heart failure in group 1 pulmonary arterial hypertension. ASAIO J.2014; 60 (1): 129–133. DOI: 10.1097/MAT.0000000000000021.
(check this in PDF content)
262
Olsson K.M., Simon A., Strueber M. et al. Extracorporeal membrane oxygenation in nonintubated patients as bridge to lung transplantation.Am. J. Transplant.2010; 10 (9): 2173–2178. DOI: 10.1111/j.1600-6143.2010.03192.x.
(check this in PDF content)
263
Fuehner T., Kuehn C., Hadem J. et al. Extracorporeal membrane oxygenation in awake patients as bridge to lung transplantation. Am. J. Respir. Crit. Care Med. 2012; 185 (7): 763–768. DOI: 10.1164/rccm.201109-1599OC.
(check this in PDF content)
264
Perrot M., Granton J.T., McRae K. et al. Impact of extracorporeal life support on outcome in patients with idiopathic pulmonary arterial hypertension awaiting lung transplantation. J. Heart Lung Transplant.2011; 30 (9): 997–1002. DOI: 10.1016/j.healun.2011.03.002.
(check this in PDF content)
265
Strueber M., Hoeper M.M., Fischer S. et al. Bridge to thoracic organ transplantation in patients with pulmonary arterial hypertension using a pumpless lung assist device. Am. J. Transplant.2009; 9 (4): 853–857. DOI: 10.1111/j. 1600-6143.2009.02549.x.
(check this in PDF content)
266
Trulock E.P., Edwards L.B., Taylor D.O. et al. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult lung and heart lung transplantation report-2006. J. Heart Lung Transplant. 2006; 25: 880–892.
(check this in PDF content)
267
Toyoda Y., Thacker J., Santos R. et al. Long-term outcome of lung and heart-lung transplantation for idiopathic pulmonary arterial hypertension. Ann. Thorac. Surg. 2008; 86: 1116–1122.
(check this in PDF content)
268
Fadel E., Mercier O., Mussot S. et al. Long-term outcome of double-lung and heart?lung transplantation for pulmonary hypertension: a comparative retrospective study of 219 patients. Eur. J. Cardiothorac. Surg. 2010; 38 (4): 277–284. DOI: 10.1016/j.athoracsur.2008.05.049.
(check this in PDF content)
269
Perrot M., Granton J.T., McRae K. et al. Outcome of patients with pulmonary arterial hypertension referred for lung transplantation: a 14-year single-center experience. J. Thorac. Cardiovasc. Surg.2012; 143 (4): 910–918. DOI: 10.1016/j.jtcvs.2011.08.055.
(check this in PDF content)
270
Christie J.D., Edwards L.B., Kucheryavaya A.Y. et al. The Registry of the International Society for Heart and Lung Transplantation: 29thadult lung and heart-lung transplant report–2012.J. Heart Lung Transplant.2012; 31: 1073– 1086.
(check this in PDF content)
271
Waddell T.K., Bennett L., Kennedy R. et al. Heart-lung or lung transplantation for Eisenmenger syndrome. J. Heart Lung Transplant. 2002; 21 (7): 731–737.
(check this in PDF content)
272
Choong C.K., Sweet S.C., Guthrie T.J. et al. Repair of congenital heart lesions combined with lung transplantation for the treatment of severe pulmonary hypertension: a 13-year experience.J. Thorac. Cardiovasc. Surg.2005; 129 (3): 661–669. DOI: 10.1016/j.jtcvs.2004.07.058.
(check this in PDF content)
273
Fleming T.R., Powers J.H. Biomarkers and surrogate endpoints in clinical trials. Statistic. Med.2012; 31 (25): 2973–2984.
(check this in PDF content)
274
Fleming T.R. Surrogate endpoints and FDA accelerated approval process.Health Affairs.2005; 24 (1): 67–78. DOI: 10.1377/hlthaff.24.1.67.
(check this in PDF content)
275
Tongers J., Schwerdtfeger B., Klein G. et al. Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. Am. Heart J.2007; 153 (1): 127–132.
(check this in PDF content)
276
Hoeper M.M., GalièN., Murali S. et al. Outcome after cardiopulmonary resuscitation in patients with pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med.2002; 165 (3): 341–344. DOI: 10.1164/ajrccm.165.3.2001090130c.
(check this in PDF content)
277
Showkathali R., Tayebjee M.H., Grapsa J. et al. Right atrial flutter isthmus ablation is feasible and results in acute clinical improvement in patients with persistent atrial flutter and severe pulmonary arterial hypertension. Int. J. Car' diol. 2011; 139 (3): 279–280. DOI: 10.1378/chest.10-1134.
(check this in PDF content)
278
Zylkowska J., Kurzyna M., Pietura R. et al. Recurrent hemoptysis: an emerging life-threatening complication in idiopathic pulmonary arterial hypertension. Chest. 2011; 139 (3): 690–693. DOI: 10.1378/chest.10-1134.
(check this in PDF content)
279
Zylkowska J., Kurzyna M., Florczyk M. et al. Pulmonary artery dilatation correlates with the risk of unexpected death in chronic arterial or thromboembolic pulmonary hypertension. Chest. 2012; 142 (6): 1406–1416. DOI: 10. 1378/chest.11-2794.
(check this in PDF content)
280
Russo V., Zompatori M., GalièN. Extensive right pulmonary artery dissection in a young patient with chronic pulmonary hypertension. Heart. 2012; 98 (3): 265–266. DOI: 10.1136/heartjnl-2011-301132.
(check this in PDF content)
281
Demerouti E.A., Manginas A.N., Athanassopoulos G.D. et al. Complications leading to sudden cardiac death in pulmonary arterial hypertension. Respir. Care.2013; 58 (7): 1246–1254. DOI: 10.4187/respcare.02252.
(check this in PDF content)
282
Lee M.S., Oyama J., Bhatia R. et al. Left main coronary artery compression from pulmonary artery enlargement due to pulmonary hypertension: a contemporary review and argument for percutaneous revascularization. Cathe' ter. Cardiovasc. Interv.2010; 76 (4): 543–550. DOI: 10.
(check this in PDF content)